Post Hoc Analysis Review: REACH2 and Early vs. Late Treatment with Ruxolitinib
Panelists engage with a post hoc analysis of the REACH2 trial comparing early versus late treatment with ruxolitinib in patients with steroid-refractory acute Graft-Versus-Host Disease.
EP: 1.Understanding Acute Graft-Versus-Host Disease
EP: 2.Standard Treatments for Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
EP: 3.REACH 2 Post Hoc Analysis Review: and The Impact of Cytopenias on Patient Outcomes
Now Viewing
EP: 4.Post Hoc Analysis Review: REACH2 and Early vs. Late Treatment with Ruxolitinib
EP: 5.Key Takeaways from Two Post Hoc Analyses of the REACH2 Trial
EP: 6.Recap: Post Hoc Analysis Highlights Impact of Cytopenias on Response Rates in Acute GVHD
Related Videos
